FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with a RET Mutation By Ogkologos - November 6, 2024 675 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LIBRETTO-531 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR From Awareness to Action: Putting Cancer Disparities in the Rearview Mirror March 21, 2024 FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs... October 16, 2025 Cancer-Free Bell Broken by Excited Patient Who Just Got Done Battling... July 17, 2019 Neoadjuvant Histotype-Tailored Treatment with Trabectedin Not Inferior to Standard Chemotherapy with... January 22, 2024 Load more HOT NEWS Jennifer Garner Shared A Video Of Her Mammogram Appointment 癌症可以在家族成员中被遗传吗？ Philanthropist Simon Collins: “I realised I could make a difference by... FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple...
